Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Events entities : Clovis oncology, inc. save search
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -3.83%
H: 0.0%
C: -9.82%
conference
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Published: 2022-04-20 (Crawled : 13:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 3.67%
H: 0.44%
C: -3.98%
conference results
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 13:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 1.85%
H: 1.4%
C: -5.82%
fap-2286 rubraca
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
Published: 2022-02-25 (Crawled : 19:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
fap-2286 ongoing trial imaging phase 1 therapy iot initiated
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -1.58%
H: 1.58%
C: -6.43%
fap-2286 preclinical pre-clinical
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 2.08%
H: 2.04%
C: -0.23%
therapy cancer
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.56%
H: 1.56%
C: 0.02%
financial results results conference
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Published: 2021-02-11 (Crawled : 20:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.73%
H: 0.73%
C: -10.56%
prostate cancer cancer symposium
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Published: 2021-02-04 (Crawled : 15:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 1.1%
H: 0.51%
C: -3.15%
cancer symposium
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.